Cargando…

Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan

OBJECTIVE: Anaplastic lymphoma kinase (ALK) rearrangement is an important oncogenic driver in some non-small cell lung cancers (NSCLC). Treatment with ALK tyrosine kinase inhibitors improves survival. The availability of diagnostic immunohistochemistry (IHC) has led to a paradigm shift in ALK testin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maraqa, Bayan, Al-Ashhab, Maxim, Sughayer, Maher A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Retrospective Clinical Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189535/ https://www.ncbi.nlm.nih.gov/pubmed/35689392 http://dx.doi.org/10.1177/03000605221104181

Ejemplares similares

Concomitant Langerhans cell histiocytosis of cervical lymph nodes in adult patients with papillary thyroid carcinoma: A report of two cases and review of the literature
por: Maraqa, Bayan, et al.
Publicado: (2021)

Mixed sex cord–stromal tumor (gynandroblastoma) with malignant morphology involving both ovaries: a case report
por: Maraqa, Bayan, et al.
Publicado: (2023)

Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study
por: Zhong, Wei-Xiang, et al.
Publicado: (2022)

Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2020)

Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Fukui, Takafumi, et al.
Publicado: (2022)

Correction to: Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2021)

Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
por: Seto, Takashi, et al.
Publicado: (2020)

Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer
por: Katayama, Ryohei
Publicado: (2018)

Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population
por: Lopes, Lisandro F, et al.
Publicado: (2012)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
por: Katayama, Ryohei, et al.
Publicado: (2015)

Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer
por: Funazo, Tomoko, et al.
Publicado: (2017)

Cytomorphological Features of Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Gene Rearrangement
por: Shukla, Saumya, et al.
Publicado: (2019)

Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
por: Zhou, Xiaoyun, et al.
Publicado: (2019)

Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements
por: Li, Shouying, et al.
Publicado: (2019)

Control of brain metastases with alectinib in anaplastic lymphoma kinase‐rearranged lung cancer
por: Kwok, Wang Chun, et al.
Publicado: (2017)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Anaplastic lymphoma kinase gene rearrangement and non-small cell lung cancer management: a step forward in personalized therapy
por: De Mello, Ramon Andrade, et al.
Publicado: (2013)

HIV-associated Non-small-cell Lung Cancer with Rearrangement of the Anaplastic Lymphoma Kinase Gene: A Report of Two Patients
por: Pichardo, Rayli, et al.
Publicado: (2019)

Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2019)

Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy
por: Park, Jangchul, et al.
Publicado: (2014)

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Asai, Nobuhiro, et al.
Publicado: (2014)

Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
por: Guo, Liting, et al.
Publicado: (2015)

Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement
por: Fu, Sha, et al.
Publicado: (2015)

Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer
por: Tan, Chye Ling, et al.
Publicado: (2016)

Efficacy and safety of ceritinib in anaplastic lymphoma kinase‐rearranged non‐small cell lung cancer: A systematic review and meta‐analysis
por: Tian, Wei, et al.
Publicado: (2020)

Pulmonary Spindle Cell Carcinoma Presenting Anaplastic Lymphoma Kinase Rearrangement
por: Sonehara, Kei, et al.
Publicado: (2023)

Anaplastic lymphoma kinase–positive anaplastic large cell lymphoma presenting as diffuse pulmonary infiltrates
por: Sato, Shuku, et al.
Publicado: (2020)

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
por: Ou, Sai-Hong Ignatius
Publicado: (2011)

Ventana immunohistochemistry assay for anaplastic lymphoma kinase gene rearrangement detection in patients with non‐small cell lung cancer: A meta‐analysis
por: Zhiwei, Wang, et al.
Publicado: (2017)

Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing
por: Wang, Ye, et al.
Publicado: (2016)

Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
por: Britschgi, Christian, et al.
Publicado: (2020)

Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study
por: El yacoubi, Hind, et al.
Publicado: (2020)

Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer
por: Kumar, Manish, et al.
Publicado: (2020)

Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data
por: Allen, Timothy Craig, et al.
Publicado: (2021)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Evaluating Solid Lung Adenocarcinoma Anaplastic Lymphoma Kinase Gene Rearrangement Using Noninvasive Radiomics Biomarkers
por: Ma, De-Ning, et al.
Publicado: (2020)

Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy
por: Sasaki, Takaaki, et al.
Publicado: (2023)

Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Wang, Li, et al.
Publicado: (2021)

Anaplastic lymphoma kinase inhibitor-associated myositis
por: Uruha, Akinori, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7cfh0v993b40j44lbuc7kcsmtk